| Sonstiges: |
- Nachgewiesen in: MEDLINE
- Sprachen: English
- Publication Type: Journal Article
- Language: English
- [Medicine (Baltimore)] 2021 May 07; Vol. 100 (18), pp. e25834.
- MeSH Terms: Chromosome Aberrations* ; Antineoplastic Combined Chemotherapy Protocols / *therapeutic use ; Bortezomib / *therapeutic use ; Multiple Myeloma / *drug therapy ; Adult ; Aged ; Aged, 80 and over ; China / epidemiology ; Female ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Multiple Myeloma / genetics ; Multiple Myeloma / mortality ; Prognosis ; Progression-Free Survival ; Retrospective Studies ; Time Factors
- References: Rollig C, Knop S, Bornhauser M. Multiple myeloma. Lancet (London, England) 2015;385:2197–208. ; Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood 2016;127:2955–62. ; Neben K, Jauch A, Bertsch U, et al. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation. Haematologica 2010;95:1150–7. ; Narita T, Inagaki A, Kobayashi T, et al. t(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs. Blood Cancer Journal 2015;5:e285. ; Hebraud B, Magrangeas F, Cleynen A, et al. Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience. Blood 2015;125:2095–100. ; Chang H, Qi X, Jiang A, et al. 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Bone Marrow Transplant 2010;45:117–21. ; Boyd KD, Ross FM, Chiecchio L, et al. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia 2012;26:349–55. ; Teoh PJ, Chung TH, Sebastian S, et al. p53 haploinsufficiency and functional abnormalities in multiple myeloma. Leukemia 2014;28:2066–74. ; Chng WJ, Dispenzieri A, Chim CS, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia 2014;28:269–77. ; Mikhael JR, Dingli D, Roy V, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc 2013;88:360–76. ; Binder M, Rajkumar SV, Ketterling RP, et al. Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma. Blood Cancer J 2017;7:e600. ; Saad AA, Sharma M, Higa GM. Treatment of multiple myeloma in the targeted therapy era. Ann Pharmacother 2009;43:329–38. ; Pineda-Roman M, Zangari M, Haessler J, et al. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Brit J Haematol 2008;140:625–34. ; Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014;28:1122–8. ; Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15:e538–548. ; San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906–17. ; Naymagon L, Abdul-Hay M. Novel agents in the treatment of multiple myeloma: a review about the future. J Hematol Oncol 2016;9:52. ; Gandolfi S, Paba Prada C, Richardson P. How I treat the young patient with multiple myeloma. Blood 2018;132:1114–24. ; Merz M, Jauch A, Hielscher T, et al. Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation. Haematologica 2017;102:1432–8. ; Merz M, Jauch A, Hielscher T, et al. Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma. Blood Adv 2018;2:01–9. ; Zavrski I, Naujokat C, Niemoller K, et al. Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion. J Cancer Res Clin Oncol 2003;129:383–91. ; Jagannath S, Richardson PG, Sonneveld P, et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 2007;21:151–7. ; Sagaster V, Ludwig H, Kaufmann H, et al. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia 2007;21:164–8. ; Kiyota M, Kobayashi T, Fuchida S, et al. Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma. Int J Hematol 2012;95:516–26. ; Mateos MV, Hernandez JM, Hernandez MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 2006;108:2165–72. ; Mateos MV, Hernandez JM, Hernandez MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Haematologica 2008;93:560–5. ; Mateos MV, Gutierrez NC, Martin-Ramos ML, et al. Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance. Blood 2011;118:4547–53. ; Biran N, Malhotra J, Bagiella E, et al. Patients with newly diagnosed multiple myeloma and chromosome 1 amplification have poor outcomes despite the use of novel triplet regimens. Am J Hematol 2014;89:616–20. ; Avet-Loiseau H, Leleu X, Roussel M, et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol 2010;28:4630–4. ; Cohen YC, Saranga A, Gatt ME. Treatment patterns and clinical outcomes in high-risk newly diagnosed multiple myeloma patients carrying the 17p deletion: an observational multi-center retrospective study. Am J Hematol 2018;93:810–5. ; Byun JM, Shin DY. Distinct predictive impact of FISH abnormality in proteasome inhibitors and immunomodulatory agents response: redefining high-risk multiple myeloma in Asian patients. Cancer Med 2018;7:831–41. ; Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol 2012;30:2946–55. ; El-Ghammaz AM, Abdelwahed E. Bortezomib-based induction improves progression-free survival of myeloma patients harboring 17p deletion and/or t(4;14) and overcomes their adverse prognosis. Ann Hematol 2016;95:1315–21.
- Grant Information: 2019YFS0104 Department of Science and Technology of Sichuan Province
- Substance Nomenclature: 69G8BD63PP (Bortezomib)
- Entry Date(s): Date Created: 20210505 Date Completed: 20210520 Latest Revision: 20230103
- Update Code: 20231215
- PubMed Central ID: PMC8104214
|
